Skip to main content

Table 1 Demographics and genotypes of participants

From: Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1

Genotype −/− −/*28 −/*6 *28/*28 *6/*28 *6/*6 p-value
Participants (n, %) 51 (48%) 18 (17%) 23 (21%) 3 (3%) 4 (4%) 8 (7%)  
Age (year), median [IQR] 44 [39–51] 43 [39–53] 42 [38–45] 42 [41–43] 46 [44–51] 44 [38–50] 0.8351
Males (n, %) 48 (94%) 15 (83%) 20 (87%) 3 (100%) 4 (100%) 8 (100%) 0.5445
Body weight (kg), median [IQR] 65 [58–72] 66 [58–72] 67 [61–74] 64 [61–77] 55 [51–59] 68 [60–73] 0.4805
Treatment naïve (n, %) 9 (18%) 5 (28%) 9 (39%) 0 (0%) 1 (25%) 2 (25%) 0.4084
CD4 cell count (cells/mL), median at the time of sampling [IQR] 486 [329–616] 431 [366–552] 378 [331–546] 434 [406–667] 500 [405–628] 540 [485–583] 0.5838
Participants with <50 HIV-1-RNA levels at the time of sampling (n, %) 50 (98%) 18 (100%) 22 (96%) 3 (100%) 4 (100%) 8 (100%) 0.9241
CD4 cell count (cells/mL), median at 24 weeks [IQR] 511 [336–603] 464 [402–623] 424 [335–528] 638 [507–819] 464 [402–563] 642 [584–669] 0.1145
Participants with <50 HIV-1-RNA levels at 24 weeks (n, %) 51 (100%) 18 (100%) 23 (100%) 3 (100%) 4 (100%) 8 (100%) 1.000
Use of antiretroviral agents (n, %)
 Tenofovir disoproxil fumarate 26 (51%) 9 (50%) 12 (52%) 2 (67%) 4 (100%) 4 (57%) 0.5559
 Abacavir sulfate 25 (49%) 9 (50%) 11 (48%) 1 (33%) 0 (0%) 3 (43%) 0.4298
 Rilpivirine hydrochloride 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (13%) 0.0286
Duration of DTG treatment (days), median [IQR] 111 [63–169] 112 [78–215] 77 [60–117] 67 [62–111] 67 [44–113] 68 [30–94] 0.3474
Food consumption        0.2698
 Fasting 16 (31%) 9 (50%) 8 (35%) 1 (33%) 3 (75%) 5 (63%)  
 Light meal 35 (69%) 9 (50%) 15 (65%) 2 (67%) 1 (25%) 3 (37%)  
HBV infection (n, %) 4 (8%) 1 (6%) 0 (0%) 0 (0%) 0 (0%) 1 (13%) 0.7028
HCV infection (n, %) 2 (4%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1.0000
  1. IQR interquartile range, HIV human immunodeficiency virus, DTG dolutegravir, HBV hepatitis B virus, HCV hepatitis C virus